8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl)-3-(trifluoromethyl)phenyl-1H-imidazol[4,5-c]quinolin-2(3H)-one is an intermediate used in the screening of anti-prostate cancer drug targeting PI3K-AKT-mTOR pathway.
ChEBI: BGT226 free base is an imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor. It has a role as an antineoplastic agent, a mTOR inhibitor and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is an imidazoquinoline, a N-arylpiperazine, a member of pyridines, an organofluorine compound and an aromatic ether. It is a conjugate base of a BGT226(1+).
